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Human loss-of-function gene variants in GPR120 have recently been identified that confer increased risk
for obesity and metabolic syndrome. In addition, GPR120 KOmice develop obesity, increased inflammation,
and insulin resistance, consistent with a role for GPR120 signaling in the metabolic syndrome and diabetes
mellitus.Obesity is the most common cause of
insulin resistance in man, and it is the
epidemic of obesity that is driving the
parallel epidemic of type 2 diabetes
(Facchini et al., 2001; Kahn et al., 2006;
Seidell, 2000). It is now recognized that
chronic tissue inflammation is a major
component of obesity-induced insulin
resistance, and this is due to the accumu-
lation of proinflammatory immune cells,
particularly in adipose tissue and liver
(Osborn and Olefsky, 2012). Recently,
Ichimura et al. (Ichimura et al., 2012)
have used human genetics approaches
to identify loss-of-function GPR120
gene variants that cause increased risk
for obesity, insulin resistance, and its
sequelae.
The literature is replete with studies
demonstrating the effects of different die-
tary lipid components on insulin sensi-
tivity, eating behavior, inflammation, and
susceptibility to metabolic disease. For
example, diets rich in saturated fatty acids
(SFAs) are associated with an increased
prevalence of obesity and type 2 diabetes
(van Dijk et al., 2009), while long-chain
polyunsaturated omega-3 fatty acid (u3-
FAs)-rich diets have anti-inflammatory
effects and may be protective against
metabolic abnormalities. GPR120 is a
lipid-sensing receptor highly expressed
in proinflammatory macrophages, and
u3-FAs exert their anti-inflammatory,
insulin-sensitizing effects through this
receptor (Oh et al., 2010) (Figure 1). For
example, when macrophages are stimu-
lated with TLR4/2 agonists or TNF-a,
activation of proinflammatory pathways
occurs, and this is largely inhibited
by u3-FA pretreatment in a GPR120
manner. A similar receptor dependency
for the insulin-sensitizing, anti-inflamma-
tory effects of u3-FAs was observed
in GPR120 KO mice, leading to the564 Cell Metabolism 15, May 2, 2012 ª2012conclusion that GPR120 is the functional
receptor/sensor for these effects of u3-
FAs (Oh et al., 2010). More recent studies
demonstrate that this same signaling
system functions in the hypothalamus.
Thus, Cintra et al. (Cintra et al., 2012)
have shown that i.c.v. administration of
u3-FAs into obese rats exerts local anti-
inflammatory effects, through the hypo-
thalamic GPR120 receptor. This results
in decreased food intake, weight reduc-
tion, and improved insulin sensitivity.
In a new paper in Nature, Ichimura
and colleagues (Ichimura et al., 2012)
have taken this field a step further by
directly exploring the GPR120 story
in man through genetic studies. Exon
sequencing was conducted in 312
obese children and adults, leading to the
identification of two nonsynonymous
GPR120 variants (R270H and R67C).
Larger groups of subjects (14,000)
were then genotyped for these variants,
demonstrating that the R270H polymor-
phism was strongly associated with
obesity and insulin resistance,with a trend
for a positive association for the R67C
variant. They took this observation a
step further by generating cell lines ex-
pressing these mutant receptors and
found that the R270H mutation caused
decreased GPR120 function in various
in vitro signaling systems. Taken together,
these studies identified a loss-of-function
GPR120 human variant associated with
obesity, insulin resistance, and its meta-
bolic sequelae.
Going from bedside to bench, this
group studied GPR120 KO mice to
explore the underlying mechanisms for
these connections. On normal chowdiets,
the GPR120 KOs showed moderate
insulin resistance with no changes in
food intake or body weight. On high-fat
diet (HFD), the GPR120 KOs gainedElsevier Inc.more weight than WT controls, but this
effect plateaued after 13 weeks. This
was associated with a decrease in energy
expenditure in young HFD GPR120
KOs (9–10 weeks), whereas differences
in energy expenditure were no longer
present when the animals reached
15 weeks of age. Although food intake
was not measured on HFD, these results
are consistent with the antiobesity effects
of GPR120 signaling in the hypothalamus.
They then went on to demonstrate that
on HFD, the GPR120 KO mice displayed
decreased insulin sensitivity compared
toWTs and exhibited all the usual charac-
teristics of the insulin-resistant state,
including glucose intolerance, hyperinsu-
linemia, a decreased hypoglycemic effect
of injected insulin, decreased insulin
signaling in WAT and liver, increased
inflammatory gene expression, and
downregulation of a variety of insulin
signaling genes. Taken together, these
are important contributions to the field,
and the authors conclude that diminished
activation of GPR120 can be an important
contributor to obesity, insulin resistance,
and tissue inflammation in both mice
and men.
A key feature in the study by Ichimura
et al. (Ichimura et al., 2012) is the genetics
analysis in man. As such, this work opens
the door for further studies and raises
a number of new questions. For example,
the genetic associations were conducted
primarily in a European population, and it
will be important to confirm and extend
these results to other ethnic groups.
Furthermore, since these investigators
have already identified obese patients
who carry the loss-of-function GPR120
variant, it would be of great interest to
conduct more detailed metabolic studies
in these subjects. For example, are the
obese subjects who carry the R270H
Figure 1. GPR120 Is an u3-FA Receptor/Sensor, and Loss of
Function Leads to Obesity and Insulin Resistance
A small fraction (3%) of obese subjects carry a loss-of-function, nonsynon-
ymous GPR120 variant (R270H) that exhibits impaired intrinsic signaling prop-
erties and inhibits u3-FA stimulation of WT GPR120. In European populations,
this variant is associated with increased risk for obesity and insulin resistance,
and high-fat-fed GPR120 KOmice also develop obesity and insulin resistance.
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erant or insulin resistant than
those without the variant, or
do they differ in some other
way? Since the R270H
variant behaves as a domi-
nant negative with respect to
GPR120 function, metabolic
differences would be ex-
pected in the R270H patients.
If such studies could be
performed, it would be of
great interest to generate an
R270H knockin mouse model
to determine how closely the
phenotype of such mice
matches the phenotype of
the patients. Given the work
from Cintra et al. (Cintra
et al., 2012) showing that
u3-FAs can operate through
hypothalamic GPR120 to
attenuate food intake, do
patients with the R270H
variant eat more? Lastly, leftopen in these studies is the question
of how subjects with and without the
GPR120 variant respond tou3-FA admin-
istration. Understandably, such studies
are well beyond the scope of their paper,
but could be of great interest for the
future.
Obesity and insulin resistance are
remarkably common problems and
represent the precursor state to type 2
diabetes (Kahn et al., 2006). Even beyond
diabetes, obesity and insulin resistanceare important risk factors for other disor-
ders such as dyslipidemia, cardiovascular
disease, certain cancers (e.g., breast,
prostate, and colon), hypertension, poly-
cystic ovarian syndrome, and sleep
apnea. In all of these conditions, there
are enormous unmet medical needs,
and new treatments are sorely needed.
The new connections Ichimura and
colleagues have shown between
GPR120 and metabolic defects in man
should heighten the importance ofCell Metabolism 15, May 2,GPR120 as a target for drug
discovery. GPR120 agonists
might lead to insulin-sensi-
tizing, anti-inflammatory, and
perhaps even antiobesity
effects, all of which would be
welcome additions to our
clinical armamentarium.
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